MHRP last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva®, administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.
A recent study led by MHRP researchers showed elevated B cell immune interactions with the envelope glycoprotein (Env) on the surface of HIV during the first month of HIV infection predict the development of broadly neutralizing antibodies (bNAbs) years later.
